A Danish study with malariamidlet as hydroxychloroquine continues, although a new study according to lægetidsskriftet The Lancet have questioned the effect.
- Now there are two larger trials, which indicates that there may be a risk by giving as hydroxychloroquine. It is certainly a sign of danger, we are aware of.
- If there are to get the type of studies or signals, then it may well be, we say that so we stop it. But we are not there yet, says professor Thomas Benfield.
He is a senior physician at the infectious disease department at Hvidovre Hospital in denmark, and is in charge of a scientific experiment with as hydroxychloroquine to coronapatienter.
the Agent has been highlighted by the president of the UNITED states, Donald Trump, who has told me that he has taken the preventive.
The new study, which is referenced in The Lancet, shows that use of as hydroxychloroquine may given increased risk of serious heart problems.
There have also in the Danish trials with the product has been one patient who received the heart rhythm is disturbed.
It led to, that the patient was taken out of the experiment, says Thomas Benfield.
the Danish medicines agency has introduced enhanced reporting requirements, so doctors should be particularly careful to report side effects.
In the background, Thomas Benfield at the present time the basis for pulling in the brake and stop the experiment.
- It reinforces, on the contrary, it must be done under very controlled circumstances, so there is a track of the side effects is no greater than the beneficial effect of the drug, he says.
Although the experiment with as hydroxychloroquine continues, is going to take some time before scientists can conclude on the effect.
the Number of inpatients cornapatienter has shown a steadily decreasing curve. And it limits the target audience, as the means may be applicable.
- We typically have zero to three admissions per day at Hvidovre Hospital. There will always be some who do not want to be with or does not meet all the criteria to be with.
- So there goes days in between, there is a suitable candidate. It will take a long time, which looks right now, says Thomas Benfield.
He puts his trust to the agent Remdesivir as 'the new standard therapy' for coronapatienter.
But the professor excludes not, therefore, that there may be patients who may have the benefit of a combined treatment with Remdesivir and as hydroxychloroquine.